Swiss pharmaceutical giant Roche presented new data on its phase three trial of an antibody cocktail on Monday.
The COVID-19 antibodysymptomatic cocktail is intended to reduce the risk of symptomatic cases of COVID-19, the company said in a statement.
The Basel-based company said its latest data set showed that subcutaneous administration of a cocktail of casirivimab and imdevimab reduced the risk of symptomatic cases by 81%.
“Of the people who still had symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptoms,” he said.
The company added that in a group of asymptomatic patients who were recently infected, the cocktail reduced the risk of progressing to symptomatic COVID-19 by 31%.
The data would be shared with regulatory authorities in Europe and the United States, the company said. (dpa / NAN)
Short Link: https://wp.me/pcj2iU-3yKN
- Police arrest 8 suspected kidnappers in Osun
- INEC engages stakeholders on polling points’ conversion in Oyo
- Opening remarks by the WHO Director-General at the high-level emergency virtual meeting of African ministers of health on the COVID-19 situation in Africa
- Coronavirus – Zimbabwe: COVID-19 update (May 7, 2021)
- Ramadan: RMAFC Chairman Mbam urges Nigerians to be tolerant, brothers’ keepers
- B-roll: African rugby teams meet to prepare for the Olympics and Olympic draft – Day 1
- Troops foil kidnap attempt, kill 1 bandit in Kaduna
- D’banj leads Nigeria to Motorsport Championships
- Super league – FIFA chief Infantino: “We need to face the problems in football together”